Report Overview:
Obesity is a medical condition caused by an increase in fat cells in the body, which can have a negative impact on health. High blood pressure, high cholesterol and heart disease are serious medical conditions associated with obesity. Obesity also increases the risk of certain diseases, such as type 2 diabetes, osteoarthritis, obstructive sleep apnea, and depression. If diet or exercise is not effective, obesity intervention devices can be used to reduce the size of the stomach or the length of the intestine, thereby reducing the ability to absorb nutrients from food.
This report provides a deep insight into the global Obesity Intervention Devices market covering all its essential aspects. This ranges from a macro overview of the market to micro details of the market size, competitive landscape, development trend, niche market, key market drivers and challenges, SWOT analysis, value chain analysis, etc.
Market Value:
The global Obesity Intervention Devices market size was estimated at USD 272 million in 2023 and is projected to reach USD 487.58 million by 2032, exhibiting a CAGR of 6.70% during the forecast period.
By Types:
• Gastric Bands
• Electrical Stimulation System
• Gastric Balloon System
• Gastric Emptying System
• Appetite Suppressors
By Applications: Hospitals
Gastroenterology clinics
Ambulatory Surgical Centers
Key players include:
• Medtronic
• EnteroMedics
• Apollo Endosurgery
• Cousin Biotech
• Aspire Bariatrics
• Obalon Therapeutics
• Including or Excluding key companies relevant to your analysis.
